Assisted Reproductive Technology (ART) is the dominant treatment segment in China's Infertility Market, valued at USD 85 million in 2024. ART encompasses procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo transfer, which have transformed fertility treatment by enabling pregnancy for couples who cannot conceive naturally. As awareness of ART grows and success rates improve, demand is rising steadily.

The China Infertility Market reflects ART's dominance. IVF remains the most commonly used procedure, with success rates reaching approximately 50% for women under 35. ICSI, used for severe male factor infertility, has expanded treatment options. Preimplantation genetic testing (PGT) is increasingly used to screen embryos for chromosomal abnormalities, improving outcomes.

Hormone therapy is the fastest-growing segment, driven by increased diagnosis of hormonal imbalances and advances in treatment. Surgery remains important for structural causes such as tubal blockage and uterine abnormalities. Fertility preservation—including egg and sperm freezing—is growing, valued at USD 38.29 million in 2024, driven by rising awareness and changing social norms. As technology continues to improve and access expands, ART is expected to remain the dominant segment in China's Infertility Market, which is projected to reach USD 691.43 million by 2035.

People Also Ask

• What is ART?
  Assisted Reproductive Technology (ART) includes fertility treatments such as IVF and ICSI that involve handling eggs or embryos to achieve pregnancy.

• How successful is IVF in China?
  IVF success rates in China reach approximately 50% for women under 35, comparable to international standards.

Tags: #ART #IVF #ICSI #ChinaHealthcare #Infertility #FertilityTreatment